The Vein and the Abyss: A Doctor’s Journey Through the World of IV Pain Medicine

Prologue: The Button

I still see her face, etched in the low light of a post-operative recovery room from early in my career.

She was pale, her brow furrowed, her thumb hovering over the small plastic button connected by a clear tube to a locked box.

This device, a Patient-Controlled Analgesia (PCA) pump, represented a kind of medical enlightenment.

It was designed to empower her, to give her agency over her own suffering.¹

The core principle is elegant: pain medicine is most effective when given before the pain becomes overwhelming, and the PCA pump allows a patient to do just that.¹

The psychological benefits are profound; studies have shown that patients using a PCA feel less anxiety, experience a greater sense of autonomy, and report higher satisfaction with their care.³

Yet, this control is a carefully constructed illusion, a delegation of power within strict, unyielding boundaries.

The real control rested with me.

I was the one who programmed the pump, setting the bolus dose (the amount of drug delivered with each push), the lockout interval (the mandatory waiting period between doses), and the hourly maximums.⁵

These safeguards exist for a single, stark reason: the drugs inside that box are so powerful that unfettered access could be fatal.

The very existence of a “lockout” is a tacit admission of the drug’s unforgiving pharmacology.

The patient’s control is nested within my control, which is itself nested within the drug’s potent nature.

This layered system of checks and balances is the essence of modern intravenous pain medicine.

There is a cardinal rule with the PCA pump: only the patient should ever press the button.¹

A well-meaning family member, seeing their loved one grimace in sleep, might be tempted to help.

But this is forbidden, because only the patient truly knows their internal state.⁷

If a patient is too sedated to press the button, they are too sedated for another dose of opioids.

This rule is more than a safety protocol; it is a profound acknowledgment of the deeply subjective, private nature of pain.

Our attempts to measure and manage it from the outside are always, at best, an approximation.

That simple button, then, is not just a tool.

It is a symbol of the trust placed in me and the immense weight of that responsibility.

What is the right dose? How does one balance the promise of profound relief against the reality of profound risk? My journey as a physician has been a long search for the wisdom to program that pump—not just with numbers and calculations, but with foresight, humility, and compassion.

Part I: The Armamentarium – A Tour of the Glass Vials

My early years in anesthesiology and pain medicine were a time of discovering the incredible power of the tools at my disposal.

The contents of these small glass vials felt like magic, capable of silencing the most primal screams of the human body.

Each drug was a different key, unlocking a different door to relief, and learning to use them felt like mastering a powerful and ancient craft.

The Old Guard: Morphine and the Opiate Legacy

I remember a patient in the intensive care unit after a major abdominal surgery.

His pain was not a simple sensation; it was a destructive force, deep and visceral, that kept his body rigid, his breathing shallow, and his heart racing.

This was the classic scenario for the most powerful tools in our armamentarium: the intravenous opioids.

These drugs—morphine, hydromorphone (often known by its brand name, Dilaudid), and fentanyl—are the direct descendants and synthetic relatives of the opium poppy, an ancient source of both solace and sorrow.⁹

They are the cornerstone of managing severe pain, especially in the first 72 hours after surgery when it is at its most intense.¹⁰

Their purpose is not merely comfort.

By controlling a patient’s pain, we enable them to take deep breaths, preventing pneumonia.

We allow them to move, reducing the risk of blood clots.

We blunt the body’s stress response, facilitating a faster, smoother recovery.¹²

The mechanism of these drugs is one of elegant subversion.

They are master keys that fit perfectly into specific locks within the central nervous system: the mu (μ), kappa (κ), and delta (δ) opioid receptors.¹⁴

Their power comes from a dual action on the neurons that transmit pain signals.

At the presynaptic nerve terminal—the sending end—opioids block calcium channels, which prevents the neuron from releasing the neurotransmitters like substance P and glutamate that scream “pain!” to the next cell in the chain.¹⁴

At the postsynaptic terminal—the receiving end—they open potassium channels.

This causes potassium ions to rush out of the cell, making it more negatively charged (a state called hyperpolarization), which makes it much harder for the neuron to fire and pass the pain signal along.¹⁴

This mechanism reveals a crucial truth about these drugs: they don’t just block the pain signal, they fundamentally alter the brain’s perception of it.¹⁶

The same receptors that mediate analgesia are also involved in mood, reward, and euphoria.¹⁴

The relief a patient feels is a combination of both reduced pain signaling and a changed emotional response to whatever pain remains.

This is why opioids are so uniquely effective for the deep

suffering component of pain, but it is also why the risk of psychological dependence is woven into their very fabric.

The different opioids are not interchangeable.

Fentanyl, for instance, has a very rapid onset and a short duration, making it ideal for the tightly controlled environment of the operating room or for brief, painful procedures.¹⁸

Morphine and hydromorphone act more slowly but last longer, making them the workhorses for sustained post-operative pain, often delivered via a PCA pump.¹⁸

Choosing the right opioid is the first step in tailoring the therapy to the patient’s specific needs.

The Firefighters: NSAIDs and the Taming of Inflammation

The scene shifts to the Emergency Department.

A young cyclist has been brought in after a nasty fall, his leg bent at an unnatural angle.

The pain is sharp, throbbing, and localized, driven by the body’s furious inflammatory response to the fractured bone.

Here, another class of IV drug takes center stage: the Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

The most common IV forms are ketorolac and ibuprofen (Caldolor).¹⁰

Unlike opioids, which work centrally in the brain and spinal cord, NSAIDs work primarily at the site of the injury.¹⁶

They act as firefighters, dousing the chemical flames of inflammation.

They do this by inhibiting cyclooxygenase (COX) enzymes, which are responsible for converting a fatty acid called arachidonic acid into inflammatory messengers known as prostaglandins.²⁰

Prostaglandins are what make an injury red, swollen, and painful.

To understand NSAIDs, one must understand the two faces of the COX enzyme.

The COX-1 isoenzyme is the “housekeeper,” constitutively expressed throughout the body to perform vital functions like protecting the stomach lining from its own acid and helping blood platelets stick together to form clots.²⁰

The COX-2 isoenzyme, by contrast, is the “inflammatory specialist,” appearing on the scene primarily when there is injury or inflammation.²⁰

Most traditional NSAIDs, including the IV forms, are non-selective; they inhibit both COX-1 and COX-2.

This is why they can cause side effects like stomach upset or bleeding.²⁰

In the clinical setting, IV NSAIDs are invaluable.

They are a first-line treatment for moderate pain in the emergency department and a critical component of a multimodal strategy in post-operative care.¹⁸

By taming inflammation, they can significantly reduce the total amount of opioids a patient requires, thereby sparing them from opioid-related side effects.¹¹

The history of these drugs taught me a crucial lesson in medical humility.

The discovery of the two COX enzymes led to a quest for a “magic bullet”: a drug that would selectively inhibit only the “bad” COX-2 enzyme, providing powerful anti-inflammatory relief without the stomach-harming effects of blocking the “good” COX-1.²¹

The resulting COX-2 inhibitors were hailed as a breakthrough.

But the story took a dark turn.

We later discovered that this very selectivity, by disrupting the delicate balance of signaling molecules in the blood vessels, could increase the risk of heart attack and stroke.²⁰

The body is a complex, interconnected system.

A targeted intervention designed to solve one problem can create new, unforeseen dangers elsewhere.

This realization was a formative part of my own struggle, pushing me away from simplistic, single-agent thinking and toward a more holistic view of my patients and my practice.

The Unsung and the Unconventional

Beyond the two giants of analgesia lies a fascinating and growing category of drugs that work through entirely different pathways.

Their rise marks a major philosophical shift in pain management.

A common scenario is a patient who, due to kidney problems or a history of ulcers, cannot take NSAIDs, and who experiences severe nausea with opioids.

For them, intravenous acetaminophen (Ofirmev) can be a godsend.¹⁰

While its precise mechanism is still debated, we know it works centrally in the brain and spinal cord, but not on opioid receptors.¹⁸

For mild to moderate pain, studies have shown it can provide relief comparable to some opioids but with a dramatically lower risk of adverse events.²²

Then there is ketamine.

Once known almost exclusively as a powerful anesthetic—and later, notoriously, as a recreational drug—ketamine has been reborn as a potent tool for severe pain.⁹

It works on a completely different neurotransmitter system, blocking the N-methyl-D-aspartate (NMDA) receptor.¹⁴

This makes it uniquely effective for certain pain states that are resistant to opioids, such as neuropathic (nerve) pain or in patients who have developed a high tolerance to opioids from chronic use.¹¹

Finally, there is the art of regional anesthesia.

Using local anesthetics like lidocaine and bupivacaine, we can deliver profound, targeted analgesia without the systemic side effects of opioids.⁹

This can be done through an epidural catheter placed near the spinal cord, a technique essential for managing the pain of labor and childbirth.⁹

It can also be done via a nerve block, where we use ultrasound to guide a needle to the specific nerves supplying an arm or leg, bathing them in anesthetic before a major orthopedic surgery.⁹

For some surgeries, we can even run a continuous, low-dose IV infusion of lidocaine, which has been shown to improve analgesia and shorten the duration of post-operative bowel dysfunction.¹¹

The growing use of this diverse group of agents signifies that we are no longer just asking, “How much pain does the patient have?” We are now asking, “What kind of pain is it?” Is it inflammatory? Is it nociceptive? Is it neuropathic? Is it centralized? The choice of drug is increasingly tailored to the underlying pathophysiology.

This is a more sophisticated, more effective, and more intellectually satisfying way to practice medicine.

Table 1: The Intravenous Analgesic Compendium

Drug Class	Representative Drugs	Primary Mechanism of Action	Typical IV Onset	Common Side Effects	Clinical Pearl
Opioids	Morphine, Hydromorphone, Fentanyl	Agonist at central μ, κ, and δ opioid receptors; alters pain perception.14	1-5 minutes (Fentanyl); 5-15 minutes (Morphine)	Sedation, respiratory depression, constipation, nausea, itching.27	Unmatched for severe, acute pain, but analgesic and adverse effects are inextricably linked to their central mechanism.
NSAIDs	Ketorolac, Ibuprofen (Caldolor)	Inhibition of COX-1 and COX-2 enzymes, reducing prostaglandin synthesis at the site of injury.20	15-30 minutes	GI upset/bleeding, kidney dysfunction, increased cardiovascular risk.20	Excellent for inflammation-driven pain and as an opioid-sparing agent in a multimodal regimen.
Acetaminophen	Acetaminophen (Ofirmev)	Central analgesic action; exact mechanism not fully understood but involves COX inhibition in the CNS.18	~15-25 minutes	Very few at therapeutic doses; risk of severe liver damage with overdose.29	A safe and effective non-opioid, non-NSAID option, especially when other classes are contraindicated.
Adjuvants	Ketamine, Lidocaine	NMDA receptor antagonist (Ketamine); Sodium channel blocker (Lidocaine).14	Minutes	Psychoperceptual effects (Ketamine); cardiac arrhythmias at high doses (Lidocaine).24	Targets alternative pain pathways, making them useful for opioid-tolerant or neuropathic pain states.

Part II: The Struggle – Navigating the Abyss

There comes a point in every physician’s journey where the initial confidence in their tools gives way to a humbling awareness of their limitations and unintended consequences.

The elegant science of pharmacology collides with the messy reality of human biology.

For me, this struggle was defined by three core challenges: the frustrating cascade of side effects, the long shadow of the opioid crisis, and the dawning recognition that sometimes, the system itself is the problem.

A Symphony of Side Effects

I can recall countless patients whose surgical recovery was derailed not by the operation itself, but by the very medications I prescribed to help them.

This is the physician’s dilemma: the double-edged sword of potent analgesia.

We are not just managing pain; we are forced to manage a symphony of drug-induced side effects that can actively work against our primary goal of healing.³¹

This is not just a simple list of annoyances; it is a cascade of interconnected problems.

Opioid-induced constipation is the most common and persistent side effect; tolerance does not develop to it as it does to other effects like sedation.²⁷

It can progress to a complete shutdown of the bowels (ileus), leading to discomfort, inability to eat, and a prolonged hospital stay.

Nausea and vomiting, another common issue, prevent a patient from taking in nutrition and transitioning to oral medications, further delaying their recovery.¹²

Sedation and confusion, especially in older patients, are not benign.

They disrupt the vital sleep needed for healing and dramatically increase the risk of falls, which can lead to new injuries and devastating complications.¹²

Even something as seemingly minor as pruritus (itching) can be maddening for a patient, robbing them of rest and adding to their overall distress.²⁷

Managing this cascade becomes a second, parallel battle.

We prescribe stool softeners and stimulant laxatives for constipation, antiemetics for nausea, and sometimes even other medications to counteract the itching.²⁷

Each new prescription adds another layer of complexity and the potential for its own side effects and drug interactions.

The clean, elegant simplicity of the initial pain management plan dissolves into a frustrating and often clumsy polypharmacy.

This was a critical point of struggle for me, the realization that our most powerful tools for facilitating recovery were simultaneously, and fundamentally, inhibiting it.

It forced me to question the opioid-centric model and begin a search for a better Way.

The Long Shadow of the Needle: Addiction and the Opioid Crisis

No single development has so profoundly reshaped the landscape of pain medicine as the opioid crisis.

I came up in an era where pain was officially designated “the fifth vital sign”.³²

We were taught, emphatically, that failing to adequately treat a patient’s pain was a clinical and moral failure.

The pendulum of practice swung hard toward aggressive opioid prescribing, driven by a well-intentioned desire to alleviate suffering.

We now live in the devastating fallout of that era.

The same intravenous lines that deliver life-saving relief in the controlled environment of the hospital ⁹ have become a symbol of addiction and death on the street.³³

The crisis is personalized in the stories of patients like Tracie, a young woman who became dependent on opioids after they were legitimately prescribed for pain following multiple surgeries for a brain tumor.³⁵

Her story is a tragic microcosm of the national epidemic: a journey from patient to addict, where the treatment becomes a new, more insidious disease.

The danger is magnified by the flood of illicitly manufactured fentanyl, a substance so potent that a minuscule amount can be deadly, turning IV drug use into a game of Russian roulette.¹⁴

This reality has placed an unbearable burden on clinicians.

We are caught in a crossfire between our foundational duty to relieve suffering and our sworn oath to do no harm.³⁶

Every decision to prescribe an opioid is now fraught with a weight and a fear that simply did not exist two decades ago.

The therapeutic relationship itself has been damaged.

Patients in legitimate, severe pain may feel they are being judged or disbelieved, their suffering viewed through a lens of suspicion.³⁷

Physicians, in turn, must be vigilant for signs of misuse and navigate a complex web of regulations, such as state-level prescription drug monitoring programs.²⁴

The trust that once formed the bedrock of the patient-physician relationship has been eroded, and the medication that was once our most reliable ally is now seen as a potential foe.

Rebuilding that trust is one of the central struggles of modern medicine.

When the System Fails: A Clinician’s Confession

The deepest and most humbling part of my struggle came with the realization that even with the best knowledge and intentions, I could fail a patient not because of a personal mistake, but because the system in which I worked was flawed.

I remember a particularly difficult case in the ICU, a complex patient with multiple organ issues, where communication breakdowns between the surgical team, the nursing staff, and my pain service led to gaps in care and a poor outcome.

It was a heartbreaking lesson in the limits of individual expertise.

Healthcare is delivered within a highly fragmented system.³⁸

Pain management in a setting like the ICU is a prime example of this complexity.

Many patients are intubated and cannot communicate their pain, forcing us to rely on behavioral scales and vital signs, which can be unreliable.³⁶

Protocols are often not standardized, leading to inconsistencies in care as patients are handed off from one provider to another.³⁹

An interprofessional team approach is essential but often difficult to execute flawlessly in a high-pressure environment.¹¹

The personal toll of this work is immense.

The constant high-stakes decisions, the emotional weight of witnessing suffering, the ever-present fear of a catastrophic adverse event, and the frustration with systemic inefficiencies all contribute to high rates of physician burnout.³⁷

This was the abyss of my struggle: the recognition that my dedication and expertise were not enough.

I began to understand that many so-called “medical errors” are, in fact, “system errors”.⁴²

The critical question is not “Who made a mistake?” but “Why did the system allow, or even encourage, this mistake to happen?” This shift in perspective, from blaming individuals to analyzing systems, was the beginning of my discovery of a new way forward.

Part III: The Discovery – A New Cartography of Pain

Emerging from the struggle required more than just new drugs; it required a new way of thinking.

The discovery was not a single “eureka” moment, but a gradual evolution in philosophy, moving from a narrow focus on the pain score to a broad, holistic view of the patient.

This new cartography of pain is built on the principles of multimodal analgesia, a systems-thinking approach, and the profound power of human connection.

The Orchestra, Not the Soloist: The Rise of Multimodal Analgesia (MMA)

Consider a patient undergoing a complex spinal fusion.

In the old paradigm, we would have relied heavily on a powerful IV opioid, like hydromorphone, delivered through a PCA pump.

The patient might have achieved a low pain score, but at the cost of being heavily sedated, nauseated, and constipated, delaying their ability to participate in physical therapy and prolonging their hospital stay.

Today, we conduct an orchestra.

This is the essence of Multimodal Analgesia (MMA): the artful combination of multiple analgesic agents, each with a different mechanism of action, used at lower individual doses.²⁶

The goal is to create an additive or synergistic effect, achieving superior pain control while minimizing the side effects associated with high doses of any single drug, particularly opioids.²⁶

The performance begins long before the first incision:

• Pre-operatively: We might start the patient on a medication like gabapentin or pregabalin. These drugs, originally developed for seizures, calm the nervous system by binding to voltage-gated calcium channels, which can pre-emptively reduce the “wind-up” of pain signals.²⁶ We might also begin a selective COX-2 inhibitor like celecoxib a day or two before surgery to get ahead of the inflammatory response.²⁶
• Intra-operatively: Instead of relying solely on general anesthesia, the anesthesiologist might place an epidural catheter or perform a regional nerve block. They might supplement this with a continuous low-dose IV infusion of ketamine or lidocaine, targeting the NMDA and sodium channel pathways, respectively.¹¹
• Post-operatively: The patient’s baseline pain control is now provided by a foundation of non-opioid medications, such as scheduled IV acetaminophen and an IV NSAID like ketorolac.¹¹ The PCA pump is still there, but it is now a supporting player rather than the star. It is programmed with a much lower dose of opioid, reserved only for moments of “breakthrough” pain that rise above the baseline analgesia.

The results of this orchestral approach are transformative.

Patients consistently report lower pain scores, consume far fewer opioids, experience fewer side effects, are able to get out of bed and work with physical therapy sooner, and ultimately have shorter and safer hospital stays.²⁶

This represents a fundamental shift from a “drug-centered” model that asks “Which single drug is strong enough?” to a “patient-centered” model that asks “What combination of interventions will best support this patient’s functional recovery?” It is a more sophisticated, more effective, and more humane approach to care.

Table 2: Principles of Multimodal Analgesia (MMA) in Practice

Clinical Scenario	Pre-emptive Analgesia	Intra-operative Techniques	Post-operative Baseline	Breakthrough Pain Management
Total Knee Arthroplasty	Gabapentin, Celecoxib	Spinal Anesthesia, Peripheral Nerve Block (e.g., adductor canal) 13	Scheduled IV Acetaminophen + Ketorolac	Low-dose oral opioid (e.g., oxycodone) 9
Major Abdominal Surgery	Gabapentin, IV Dexamethasone	Thoracic Epidural Analgesia, IV Lidocaine Infusion 9	Scheduled IV Acetaminophen	Low-dose IV Opioid PCA (e.g., Hydromorphone) 26
Acute Rib Fractures (Trauma)	N/A (acute setting)	Intercostal Nerve Blocks or Erector Spinae Plane (ESP) Block 11	Scheduled IV Acetaminophen + IV Ketorolac	Low-dose IV Opioid PCA (e.g., Fentanyl) 18

Pain as an Ecosystem: A Systems-Thinking Approach

The most profound discovery of my career was conceptual.

I realized that treating complex pain, especially chronic pain, is not like fixing a broken machine.

It is like managing a fragile ecosystem.

A machine has discrete parts, and a single broken component can be replaced to restore function.

An ecosystem is a web of dynamic, interconnected relationships, where an intervention in one area can have cascading and often unpredictable effects on the whole.³⁸

This metaphor provided me with a new and powerful framework for understanding my patients and my role.

This approach aligns beautifully with the twelve guiding principles of ecosystem management, which can be adapted to create a more holistic model of pain care ⁴⁴:

• Principle 1 (Societal Choice): The goals of pain management are not dictated by the physician but are a matter of societal choice between the patient and the clinician. What does “success” look like for this individual? Is it running a marathon, or is it being able to play with their grandchildren on the floor?
• Principle 3 (Consider Adjacent Ecosystems): We must consider the effects of our actions on adjacent systems. Treating a patient’s back pain with high-dose opioids that cause sedation and confusion negatively impacts their “family ecosystem” and their “work ecosystem.”
• Principle 5 (Conserve Structure & Function): The priority target is the conservation of the ecosystem’s structure and function. The goal is not simply to achieve a pain score of zero, but to restore the patient’s ability to live a full and functional life.
• Principle 6 (Manage within Limits): Ecosystems must be managed within the limits of their functioning. We must respect the body’s biological limits and not pursue a “cure” that causes more harm than good, a key lesson from the opioid crisis.
• Principle 8 (Long-term Objectives): Objectives should be set for the long term. The goal is sustainable pain management and a durable quality of life, not just fleeting relief at any cost.
• Principle 12 (Involve All Sectors): True ecosystem management involves all relevant sectors. This is the principle of interdisciplinary care, bringing together physicians, physical therapists, psychologists, social workers, and the patient’s family to manage the pain ecosystem collaboratively.¹¹

This systems-thinking approach, which mirrors the formal biopsychosocial model of pain ⁴⁰, fundamentally redefines success.

If pain is just a broken part, success is its elimination.

If pain is a dysfunctional ecosystem, success is restoring balance and function, even if some pain remains.

This is a more realistic, hopeful, and sustainable paradigm for both patient and physician, and it helps protect clinicians from the burnout that comes from chasing an impossible ideal.³⁷

Beyond the Molecule: The Power of Narrative and Connection

My final discovery was that the most potent analgesic in my armamentarium is not a molecule in a vial.

It is the act of listening.

Patients suffering from chronic pain often struggle to articulate their experience in a way that is heard, understood, or taken seriously by the medical establishment.⁴⁶

We ask them to collapse their multifaceted suffering—the physical sensations, the emotional distress, the social isolation, the loss of identity—into a single, inadequate number on a 0-10 scale.⁴⁶

This decontextualizes their experience and is detrimental to their care.

The turning point for many of my patients has not been a new drug or a novel procedure, but a moment of true human connection.

By inviting them to tell their story, to construct their “illness narrative,” we engage in a therapeutic act.⁴⁸

The process of narration can itself restore a sense of order, meaning, and agency to a life thrown into chaos by pain.⁴⁶

It allows me to understand their unique “pain recipe” ⁴⁹—the specific blend of biological, psychological, and social ingredients that contribute to their suffering.

This journey has reshaped my own professional narrative.

I began my career as a confident technician, armed with powerful drugs to vanquish pain.

I have become a humble guide, helping patients navigate the complex and often treacherous ecosystem of their own bodies and lives.

The old model of care was paternalistic: I diagnose, I prescribe, you comply.

The new model is a collaborative partnership.

The patient is the expert on their lived experience; I am an expert on the tools and strategies that might help.

Together, we co-create a plan.

This transforms the practice of medicine from a series of technical interventions into a genuine therapeutic relationship.

Epilogue: The Hand That Holds

I find myself back in that post-operative room, looking at the patient with the PCA pump.

The scene is the same, but my understanding is now profoundly different.

I no longer see just a button and a box.

I see the intricate pharmacology of the opioid inside, the delicate dance of neurotransmitters at the synapse.

I see the potential cascade of side effects—the constipation, the nausea, the clouded mind—that could hinder recovery.

I see the long, dark shadow of the opioid crisis and the societal wound it has left.

I see the complex system of the hospital—the nurses, the surgeons, the pharmacists—all of whom must work in concert for this one patient to heal safely.

And most importantly, I see the patient’s personal story, the unique life and fears and hopes that led them to this moment of vulnerability.

My focus has shifted.

It is no longer just on the patient’s hand, hovering over the button that delivers the medicine.

It is on my own hand, metaphorically, holding the entire system of care.

My role is not merely to provide a tool, but to hold the space for healing.

It is to manage the ecosystem, to listen to the narrative, and to guide the patient with the humility and wisdom gained through a long journey through the vein and the abyss.

The goal is not just to silence the pain, but to help restore the person.

In that shared humanity lies the truest and most lasting form of relief.

Works cited

1. Pain Management: Patient-Controlled Analgesia (PCA) Pump …, accessed on August 12, 2025, https://www.nyp.org/healthlibrary/articles/pain-management-patient-controlled-analgesia-pca-pump
2. Patient-Controlled Analgesia Pumps | Johns Hopkins Medicine, accessed on August 12, 2025, https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/patientcontrolled-analgesia-pumps
3. Patient-Controlled Anesthesia (PCA): What You Need to Know, accessed on August 12, 2025, https://www.verywellhealth.com/patient-controlled-anesthesia-5092508
4. 3 Advantages of Patient-Controlled Analgesia Pumps – Med One Group, accessed on August 12, 2025, https://www.medonegroup.com/aboutus/blog/3-advantages-of-patient-controlled-analgesia-pumps
5. Using a PCA Pump | Saint Luke’s Health System, accessed on August 12, 2025, https://www.saintlukeskc.org/health-library/using-pca-pump
6. Patient-Controlled Analgesia – StatPearls – NCBI Bookshelf, accessed on August 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK551610/
7. Patient Controlled Analgesia (PCA) FAQ’s – Emory Healthcare, accessed on August 12, 2025, https://www.emoryhealthcare.org/centers-programs/pain-center/wellness/pca-faq
8. Patient-Controlled Analgesia (PCA) – Memorial Sloan Kettering Cancer Center, accessed on August 12, 2025, https://www.mskcc.org/cancer-care/patient-education/patient-controlled-analgesia-pca
9. Pain medicines after surgery – Mayo Clinic, accessed on August 12, 2025, https://www.mayoclinic.org/healthy-lifestyle/consumer-health/in-depth/pain-medications/art-20046452
10. What’s in Your IV Pain Meds? – Verywell Health, accessed on August 12, 2025, https://www.verywellhealth.com/intravenous-pain-medications-3156872
11. Postoperative Pain Control – StatPearls – NCBI Bookshelf, accessed on August 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK544298/
12. Pain Medications After Surgery: Types, Benefits & Risks, accessed on August 12, 2025, https://my.clevelandclinic.org/health/articles/11307-pain-control-after-surgery
13. Pain Medications After Orthopaedic Surgery – OrthoInfo – AAOS, accessed on August 12, 2025, https://orthoinfo.aaos.org/en/recovery/managing-pain-with-medications/
14. Opioid Analgesics – StatPearls – NCBI Bookshelf, accessed on August 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK459161/
15. Opioid Prescribing – StatPearls – NCBI Bookshelf, accessed on August 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK551720/
16. Analgesics: Uses, Treatment, Risks – Cleveland Clinic, accessed on August 12, 2025, https://my.clevelandclinic.org/health/drugs/21483-analgesics
17. Physiology, Opioid Receptor – StatPearls – NCBI Bookshelf, accessed on August 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK546642/
18. Acute pain control – SAEM, accessed on August 12, 2025, https://www.saem.org/about-saem/academies-interest-groups-affiliates2/cdem/for-students/online-education/m3-curriculum/group-acute-pain-control/acute-pain-control
19. Pain Management in the Emergency Department: a Review Article on Options and Methods, accessed on August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6548151/
20. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) – StatPearls – NCBI …, accessed on August 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK547742/
21. Nonsteroidal anti-inflammatory drug – Wikipedia, accessed on August 12, 2025, https://en.wikipedia.org/wiki/Nonsteroidal_anti-inflammatory_drug
22. IV Acetaminophen for Acute Pain in Emergency Departments – NCBI Bookshelf, accessed on August 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK598217/
23. Chronic pain: Medication decisions – Mayo Clinic, accessed on August 12, 2025, https://www.mayoclinic.org/diseases-conditions/back-pain/in-depth/chronic-pain-medication-decisions/art-20360371
24. AAEM White Paper on Acute Pain Management in the Emergency Department, accessed on August 12, 2025, https://www.aaem.org/statements/aaem-white-paper-on-acute-pain-management-in-the-emergency-department/
25. Intravenous/Intramuscular Labor Pain Relief – Brigham and Women’s Hospital, accessed on August 12, 2025, https://www.brighamandwomens.org/anesthesiology-and-pain-medicine/pain-free-birthing/intravenous-intramuscular-pain-relief
26. Anesthesia and postoperative pain control—multimodal anesthesia …, accessed on August 12, 2025, https://jss.amegroups.org/article/view/4671/html
27. Four Strategies for Managing Opioid-Induced Side Effects in Older …, accessed on August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4418642/
28. Side effects of opioids | Faculty of Pain Medicine, accessed on August 12, 2025, https://fpm.ac.uk/opioids-aware-clinical-use-opioids/side-effects-opioids
29. Pain Relievers – MedlinePlus, accessed on August 12, 2025, https://medlineplus.gov/painrelievers.html
30. Painkillers and NSAIDs | Side-effects, uses, time to work – Versus Arthritis, accessed on August 12, 2025, https://versusarthritis.org/about-arthritis/treatments/drugs/painkillers-and-nsaids/
31. Self-reports of medication side effects and pain-related activity interference in patients with chronic pain: A longitudinal cohort study – PMC, accessed on August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4431924/
32. Oregon Medical Board : Pain Management : Statements of Philosophy, accessed on August 12, 2025, https://www.oregon.gov/omb/board/philosophy/pages/pain-management.aspx
33. IV Drug Use & Opioid Addiction, accessed on August 12, 2025, https://drugfree.org/article/iv-drug-use-video-series/
34. Opioids and Injection Drug Use – MN Dept. of Health, accessed on August 12, 2025, https://www.health.state.mn.us/communities/opioids/basics/intravenous.html
35. Chronic Pain: Tracie’s Story | Johns Hopkins Medicine, accessed on August 12, 2025, https://www.hopkinsmedicine.org/health/conditions-and-diseases/chronic-pain/patient-story-tracie
36. Pain Management Challenges in Acute and Critically Ill Patients …, accessed on August 12, 2025, https://aacnjournals.org/aacnacconline/article/30/4/318/30598/Pain-Management-Challenges-in-Acute-and-Critically
37. Trauma-informed high impact chronic pain care | This Changed My Practice (TCMP) by UBC CPD, accessed on August 12, 2025, https://thischangedmypractice.com/trauma-informed-hicp-care/
38. Five Ways to Incorporate Systems Thinking into Healthcare Organizations | Biomedical Instrumentation & Technology – AAMI Array, accessed on August 12, 2025, https://array.aami.org/doi/full/10.2345/0899-8205-48.s2.31
39. Pain Management Strategies in Intensive Care Unit: Challenges and Best Practice – PMC, accessed on August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11368475/
40. IV. Managing chronic pain: a clinical challenge: new SIGN guidelines provide a practical evidence-based approach and identify research gaps | BJA: British Journal of Anaesthesia | Oxford Academic, accessed on August 12, 2025, https://academic.oup.com/bja/article/112/1/9/244369
41. Systems thinking to improve healthcare | The BMJ, accessed on August 12, 2025, https://www.bmj.com/content/384/bmj.q105
42. A systems approach to healthcare: from thinking to practice – PMC, accessed on August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6502599/
43. www.integratedecosystemassessment.noaa.gov, accessed on August 12, 2025, https://www.integratedecosystemassessment.noaa.gov/about-iea/ecosystem-based-management#:~:text=EBM%20manages%20ecosystem%20components%20as,a%20coupled%20socio%2Decological%20system.
44. Annex 1. Twelve guiding principles for ecosystem management – IUCN, accessed on August 12, 2025, https://iucn.org/sites/default/files/import/downloads/annexes_iucn_poyang_lake_report_8_17_10.pdf
45. Three roles of narratives in the treatment of chronic pain – EngagedScholarship@CSU, accessed on August 12, 2025, https://engagedscholarship.csuohio.edu/cgi/viewcontent.cgi?article=1087&context=clphil_facpub
46. Incorporating personal narratives in positive psychology interventions to manage chronic pain – PMC, accessed on August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10588179/
47. Incorporating personal narratives in positive psychology interventions to manage chronic pain – Frontiers, accessed on August 12, 2025, https://www.frontiersin.org/journals/pain-research/articles/10.3389/fpain.2023.1253310/full
48. Full article: “Power of Storytelling”: A Content Analysis of Chronic Pain Narratives on YouTube – Taylor & Francis Online, accessed on August 12, 2025, https://www.tandfonline.com/doi/full/10.1080/24740527.2021.1929117
49. This Book Changed My Relationship to Pain – YouTube, accessed on August 12, 2025, https://www.youtube.com/watch?v=gZdtrY8NuUc